Phio Pharmaceuticals Corp.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Phio Pharmaceuticals Corp.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than almost all Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 9,079% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-1,435.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than almost all Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Phio Pharmaceuticals Corp. made a loss over the last year. Phio Pharmaceuticals Corp. owes $0.12 for every $1 it owns. Phio Pharmaceuticals Corp. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPhio Pharmaceuticals Corp. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.80The share price is 0.80 times Phio Pharmaceuticals Corp.'s book value per share, lower than 84% of Healthcare companies in United States.
Market cap
$10 MThe total market value of all of Phio Pharmaceuticals Corp.'s shares at today's price (share price × number of shares), smaller than 88% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$13 MWhat Phio Pharmaceuticals Corp. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.08Net worth divided by the number of shares. The share price of $0.87 is 0.8 times this, which is the P/B above.
Return on equity (ROE)
-113.7%Phio Pharmaceuticals Corp. lost 113.7% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
Owes vs Owns
0.12×Phio Pharmaceuticals Corp. owes $0.12 for every $1 it owns (low), lower than 84% of Healthcare companies in United States.
Dividend yield
NonePhio Pharmaceuticals Corp. does not currently pay a dividend.
Profit growth
LossPhio Pharmaceuticals Corp. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Phio Pharmaceuticals Corp.: $10 M ÷ $13 M (30 Jun 2026) = 0.8.
What is Phio Pharmaceuticals Corp.'s return on equity?
Phio Pharmaceuticals Corp. lost 113.7% of its shareholders' money over the last year, lower than 74% of Healthcare companies in United States.
How much does Phio Pharmaceuticals Corp. owe compared with what it owns?
Phio Pharmaceuticals Corp. owes $0.12 for every $1 it owns (low), lower than 84% of Healthcare companies in United States.
Does Phio Pharmaceuticals Corp. pay a dividend?
No. Phio Pharmaceuticals Corp. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.